DRUG
Cagrisema
Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously using device 1 or device 2.
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
Status
Withdrawn
Phase
Phase 3
Enrollment
0
Locations
116
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
This study is being done to find out how well a medicine called CagriSema helps people with overweight or obesity lose weight. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance using a computer program, so neither participants nor study staff will know which treatment is given. The study will last for about one year.
Interventions
Treatment arms and agents.
DRUG
Placebo CagriSema
Placebo matched to Cagrilintide and Placebo matched to Semaglutide will be administered subcutaneously using device 1 or device 2.
Timeline
From registration to results.
First posted
Jan 22, 2026
Study start
Jun 22, 2026
Primary completion
Nov 29, 2027
Study completion
Jan 17, 2028
Results posted
Not reported
Registry updated
Jul 9, 2026
Outcomes
What the study measures.
Primary outcomes
Relative change in body weight
Time frame · From baseline (week 0) to end of treatment (week 44)
Measured in percentage (%).
Secondary outcomes
Number of TEAEs (treatment emergent adverse events)
Time frame · From baseline (week 0) to end of study (week 51)
Measured in count of events.
Number of TESAEs (Treatment emergent serious adverse events)
Time frame · From baseline (week 0) to end of study (week 51)
Measured in count of events.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Male or female (sex at birth) * Age 18 years or above at the time of signing the informing consent. * Body Mass Index (BMI) is greater than or equal to (\>= ) 30.0 kilograms per square metre (kg/m\^2) or BMI \>= 27.0 kg/m\^2 with the presence of at least one obesity-related complication including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. Exclusion Criteria: * Glycosylated haemoglobin (HbA1c) \>= 6.5 % (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes. * Previous exposure to CagriSema in a clinical study.
Study locations
116 registered sites.
Bulgaria · Denmark · Greece · Hungary · Malaysia · Poland · Portugal · Romania · Slovakia · South Africa · Switzerland · Taiwan · Thailand · United States. Showing up to 24 locations stored in the fast local snapshot.
Uni of Alabama at Birmingham
Birmingham, Alabama, United States
Cahaba Research
Pelham, Alabama, United States
Advanced Investigative Medicine, Inc.
Hawthorne, California, United States
Southern Cal Clinical Research
Santa Ana, California, United States
Encompass Clinical Research_Spring Valley
Spring Valley, California, United States
Chase Medical Research LLC
Waterbury, Connecticut, United States
NextPhase Research
Hollywood, Florida, United States
Oceane 7 Medical & Research Center, Inc.
Miami, Florida, United States
ForCare Clinical Research
Tampa, Florida, United States
EBGS Clinical Research Center, LLC
Snellville, Georgia, United States
Rophe Adult & Pediatric Medicine
Union City, Georgia, United States
Rocky Mountain Diabetes and Osteoporosis Center
Idaho Falls, Idaho, United States
PGM Research of Christie Clinic
Champaign, Illinois, United States
Arcturus HC PLC Troy Med Res
Troy, Michigan, United States
Anointed Nephrology & HTN, LLC
Brookhaven, Mississippi, United States
Palm Research Center Inc.
Las Vegas, Nevada, United States
Palm Research Center Inc.
Las Vegas, Nevada, United States
Weill Medical College of Cornell University
New York, New York, United States
Alliance for Multispecialty Research
Norman, Oklahoma, United States
Tribe Clinical Research LLC
Greer, South Carolina, United States
Walker Family Care
Little River, South Carolina, United States
Elligo Clin Res Centre
Austin, Texas, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Forefront Med Res Inst PLLC
Harlingen, Texas, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Semaglutide.
NCT IDStudyPhase / statusEnrollmentUpdated
Fibrosis Lessens After Metabolic Surgery
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease
Oelisoa Andriankaja · Obesity · Dental Care for Children
Not applicable
Not yet recruiting
50
2026-07
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
Terrestrial Bio, Inc. · Overweight and/or Obesity
Phase 1
Recruiting
62
2026-07
Tirzepatide Impact Assessment Study
Texas Tech University · Obesity & Overweight · Cardiometabolic Health Indicators
Not applicable
Recruiting
27
2026-07
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes
Phase 3
Completed
884
2026-07
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Novo Nordisk · Obesity · Type 2 Diabetes
Phase 3
Recruiting
2,500
2026-07
Myocardial Metabolic Flux in Pulmonary Arterial Hypertension
Imperial College London · Pulmonary Arterial Hypertension
Phase 2
Not yet recruiting
32
2026-07
Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.
China-Japan Friendship Hospital · Obesity
Not applicable
Recruiting
400
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.